<DOC>
	<DOCNO>NCT01156883</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together steroid therapy may kill cancer cell . PURPOSE : This clinical trial study side effect combination chemotherapy treat young adult patient acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Adult Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To determine feasibility combination chemotherapy young adult patient acute lymphoid leukemia . - To determine complete response rate end induction therapy patient . - To determine overall survival patient treat regimen . - To determine disease-free survival patient treat regimen . - To determine event-free survival patient treat regimen . - To determine toxicity regimen . - To determine compliance relate dose intensity . OUTLINE : - Steroids prephase therapy : All patient receive steroid ( i.e. , prednisone methylprednisolone ) methotrexate . - Induction therapy ( induction Ia follow Ib ) : Patients receive induction Ia comprise vincristine , daunorubicin hydrochloride , asparaginase , prednisone . They receive induction Ib comprise cyclophosphamide , mercaptopurine , cytarabine . Patients achieve hematological remission proceed consolidation therapy . - Consolidation therapy : Patients receive consolidation therapy accord risk group . - Standard-risk patient : Patients receive high-dose methotrexate mercaptopurine . - High-risk patient : Patients receive consolidation therapy 3 step . - Step 1 : Patients receive dexamethasone , vincristine , methotrexate , cytarabine , asparaginase . - Step 2 : Patients receive dexamethasone , vindesine , methotrexate , ifosfamide , asparaginase , daunorubicin hydrochloride . - Step 3 : Patients receive dexamethasone , cytarabine , asparaginase . After completion consolidation therapy , patient proceed reinduction therapy . - Reinduction therapy ( reinduction IIa follow IIb ) : Patients receive reinduction IIa comprise vincristine , doxorubicin hydrochloride , asparaginase , dexamethasone . Patients receive reinduction IIb comprise cyclophosphamide , thioguanine , cytarabine .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoid leukemia , meet follow criterion : Nonmature Bcell disease NonPhiladelphia chromosome positive disease T cell Bcell phenotype PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Prior pretreatment antiblastic chemotherapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
</DOC>